JP2018517731A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517731A5 JP2018517731A5 JP2017564886A JP2017564886A JP2018517731A5 JP 2018517731 A5 JP2018517731 A5 JP 2018517731A5 JP 2017564886 A JP2017564886 A JP 2017564886A JP 2017564886 A JP2017564886 A JP 2017564886A JP 2018517731 A5 JP2018517731 A5 JP 2018517731A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- unsubstituted
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175510P | 2015-06-15 | 2015-06-15 | |
| US62/175,510 | 2015-06-15 | ||
| PCT/CN2016/085806 WO2016202253A1 (en) | 2015-06-15 | 2016-06-15 | Nrf2 regulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517731A JP2018517731A (ja) | 2018-07-05 |
| JP2018517731A5 true JP2018517731A5 (enExample) | 2020-11-12 |
| JP6789995B2 JP6789995B2 (ja) | 2020-11-25 |
Family
ID=57545504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564886A Active JP6789995B2 (ja) | 2015-06-15 | 2016-06-15 | Ｎｒｆ２レギュレーター |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10604509B2 (enExample) |
| EP (2) | EP3307739B1 (enExample) |
| JP (1) | JP6789995B2 (enExample) |
| KR (1) | KR102675041B1 (enExample) |
| CN (1) | CN108112251B (enExample) |
| AU (1) | AU2016279388B2 (enExample) |
| CA (1) | CA2988338C (enExample) |
| CL (1) | CL2017003226A1 (enExample) |
| CO (1) | CO2017012995A2 (enExample) |
| CY (1) | CY1123853T1 (enExample) |
| DK (2) | DK3782996T3 (enExample) |
| DO (1) | DOP2017000298A (enExample) |
| EA (1) | EA035864B1 (enExample) |
| ES (2) | ES2980945T3 (enExample) |
| FI (1) | FI3782996T3 (enExample) |
| HR (2) | HRP20240666T1 (enExample) |
| HU (2) | HUE052919T2 (enExample) |
| IL (1) | IL256297B (enExample) |
| LT (2) | LT3782996T (enExample) |
| MA (1) | MA52309B1 (enExample) |
| MX (1) | MX375352B (enExample) |
| MY (1) | MY207356A (enExample) |
| PE (1) | PE20180799A1 (enExample) |
| PH (1) | PH12017502255B1 (enExample) |
| PL (2) | PL3782996T3 (enExample) |
| PT (2) | PT3307739T (enExample) |
| RS (2) | RS61302B1 (enExample) |
| SI (2) | SI3782996T1 (enExample) |
| SM (1) | SMT202400207T1 (enExample) |
| WO (1) | WO2016202253A1 (enExample) |
| ZA (1) | ZA201708145B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2834490T3 (es) | 2015-06-15 | 2021-06-17 | Glaxosmithkline Ip Dev Ltd | Reguladores de NRF2 |
| EP3371167A1 (en) * | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| EP3555078B1 (en) | 2016-12-14 | 2024-03-27 | GlaxoSmithKline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 activators |
| US20220002272A1 (en) * | 2016-12-14 | 2022-01-06 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl lactams as nrf2 activators |
| WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
| US11059816B2 (en) | 2016-12-15 | 2021-07-13 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as NRF2 activators |
| KR20190091455A (ko) | 2016-12-15 | 2019-08-06 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 화합물 |
| CA3063934A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Kinase inhibitors and uses thereof |
| WO2019116231A1 (en) | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| CA3095908A1 (en) * | 2018-04-06 | 2019-10-10 | The Board Of Trustees Of The University Of Illinois | 1,4-substituted isoquinoline inhibitors of keap1/nrf2 protein-protein interaction |
| PE20211205A1 (es) | 2018-08-20 | 2021-07-05 | Janssen Pharmaceutica Nv | Inhibidores de la interaccion proteina-proteina keap1-nrf2 |
| AU2019391942B2 (en) | 2018-12-05 | 2024-03-21 | Scohia Pharma, Inc. | Macrocyclic compound and use thereof |
| AU2020222080C1 (en) * | 2019-02-15 | 2022-09-29 | Glaxosmithkline Intellectual Property Development Limited | Hydroxypyridoxazepines as Nrf2 activators |
| JP7524899B2 (ja) * | 2019-05-31 | 2024-07-30 | Ｕｂｅ株式会社 | ベンゾトリアゾール誘導体 |
| CN114080389B (zh) | 2019-07-03 | 2024-08-30 | 千寿制药株式会社 | Nrf2活性化化合物 |
| CN110845435B (zh) | 2019-11-28 | 2021-06-08 | 中国药科大学 | 一种过氧化氢响应型Keap1-Nrf2 PPI抑制剂前药、制备方法及其医药用途 |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| CN114539085B (zh) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | 一种脲基衍生物的制备 |
| KR20230127268A (ko) | 2020-12-28 | 2023-08-31 | 센주 세이야꾸 가부시키가이샤 | Nrf2 활성화 화합물 |
| EP4516792A1 (en) | 2022-04-28 | 2025-03-05 | Kyoto Pharmaceutical Industries, Ltd. | Benzothiophene compound |
| KR20250004844A (ko) * | 2022-04-28 | 2025-01-08 | 다이이찌 산쿄 가부시키가이샤 | 벤조트리아졸 화합물 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| AT396333B (de) | 1982-10-08 | 1993-08-25 | Glaxo Group Ltd | Vorrichtung zur verabreichung von medikamenten an patienten, einrichtung mit mehreren solchen vorrichtungen und traeger mit medikamentbehaeltern hiefuer |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| DK163640C (da) | 1985-07-30 | 1992-08-17 | Glaxo Group Ltd | Apparat til administrering af medikamenter |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| SK280968B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji |
| IL99537A (en) | 1990-09-27 | 1995-11-27 | Merck & Co Inc | Fibrinogen receptor antagonists and pharmaceutical compositions containing them |
| US5217994A (en) | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| JP3342485B2 (ja) | 1991-12-10 | 2002-11-11 | 塩野義製薬株式会社 | 芳香族スルホンアミド系ヒドロキサム酸誘導体 |
| DE4220983A1 (de) * | 1992-06-26 | 1994-01-05 | Bayer Ag | Imidazolyl-substituierte Phenylpropion- und -zimtsäurederivate |
| JPH10501222A (ja) | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CA2435829A1 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| WO2002080899A1 (fr) | 2001-03-30 | 2002-10-17 | Eisai Co., Ltd. | Agent de traitement de maladie digestive |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| HRP20080382A2 (en) | 2001-09-21 | 2008-12-31 | Bristol-Myers Squibb Company A Delaware (Usa) Corporation | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS |
| US20040157919A1 (en) | 2002-01-25 | 2004-08-12 | Yong-Qian Wu | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| JPWO2004007464A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | イミダゾール誘導体 |
| CN101333192A (zh) | 2003-04-03 | 2008-12-31 | 默克公司 | 作为钠通道阻滞剂的联芳基取代吡唑 |
| WO2006044133A1 (en) | 2004-09-24 | 2006-04-27 | Axys Pharmaceuticals, Inc. | Active ketone inhibitors of tryptase |
| US7989445B2 (en) | 2005-04-28 | 2011-08-02 | Takeda Pharmaceutical Company Limited | Thienopyrimidone compound |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| AU2008296974B2 (en) | 2007-09-06 | 2013-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2010005922A1 (en) | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
| WO2010099054A2 (en) | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20140256767A1 (en) * | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| US9382188B2 (en) | 2012-02-13 | 2016-07-05 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| WO2013155528A2 (en) | 2012-04-13 | 2013-10-17 | Fasgen, Inc. | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
| US20160046616A1 (en) * | 2013-03-15 | 2016-02-18 | The Johns Hopkins University | Nrf2 small molecule inhibitors for cancer therapy |
| KR102301867B1 (ko) * | 2013-12-18 | 2021-09-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Nrf2 조절제 |
| ES2834490T3 (es) | 2015-06-15 | 2021-06-17 | Glaxosmithkline Ip Dev Ltd | Reguladores de NRF2 |
| US20180179167A1 (en) | 2015-06-15 | 2018-06-28 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 REGULATORS |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| EP3371167A1 (en) | 2015-10-06 | 2018-09-12 | GlaxoSmithKline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
-
2016
- 2016-06-15 US US15/736,075 patent/US10604509B2/en active Active
- 2016-06-15 ES ES20200207T patent/ES2980945T3/es active Active
- 2016-06-15 HR HRP20240666TT patent/HRP20240666T1/hr unknown
- 2016-06-15 WO PCT/CN2016/085806 patent/WO2016202253A1/en not_active Ceased
- 2016-06-15 CA CA2988338A patent/CA2988338C/en active Active
- 2016-06-15 RS RS20210012A patent/RS61302B1/sr unknown
- 2016-06-15 KR KR1020187000828A patent/KR102675041B1/ko active Active
- 2016-06-15 PL PL20200207.7T patent/PL3782996T3/pl unknown
- 2016-06-15 ES ES16810994T patent/ES2841574T3/es active Active
- 2016-06-15 FI FIEP20200207.7T patent/FI3782996T3/fi active
- 2016-06-15 HR HRP20202036TT patent/HRP20202036T1/hr unknown
- 2016-06-15 SI SI201631820T patent/SI3782996T1/sl unknown
- 2016-06-15 PH PH1/2017/502255A patent/PH12017502255B1/en unknown
- 2016-06-15 MA MA52309A patent/MA52309B1/fr unknown
- 2016-06-15 AU AU2016279388A patent/AU2016279388B2/en active Active
- 2016-06-15 PT PT168109940T patent/PT3307739T/pt unknown
- 2016-06-15 EA EA201890052A patent/EA035864B1/ru not_active IP Right Cessation
- 2016-06-15 EP EP16810994.0A patent/EP3307739B1/en active Active
- 2016-06-15 SI SI201631036T patent/SI3307739T1/sl unknown
- 2016-06-15 CN CN201680048338.1A patent/CN108112251B/zh active Active
- 2016-06-15 RS RS20240608A patent/RS65562B1/sr unknown
- 2016-06-15 PL PL16810994T patent/PL3307739T3/pl unknown
- 2016-06-15 EP EP20200207.7A patent/EP3782996B1/en active Active
- 2016-06-15 MX MX2017016405A patent/MX375352B/es active IP Right Grant
- 2016-06-15 MY MYPI2017704768A patent/MY207356A/en unknown
- 2016-06-15 SM SM20240207T patent/SMT202400207T1/it unknown
- 2016-06-15 HU HUE16810994A patent/HUE052919T2/hu unknown
- 2016-06-15 JP JP2017564886A patent/JP6789995B2/ja active Active
- 2016-06-15 LT LTEP20200207.7T patent/LT3782996T/lt unknown
- 2016-06-15 DK DK20200207.7T patent/DK3782996T3/da active
- 2016-06-15 PE PE2017002744A patent/PE20180799A1/es unknown
- 2016-06-15 HU HUE20200207A patent/HUE066668T2/hu unknown
- 2016-06-15 PT PT202002077T patent/PT3782996T/pt unknown
- 2016-06-15 LT LTEP16810994.0T patent/LT3307739T/lt unknown
- 2016-06-15 DK DK16810994.0T patent/DK3307739T3/da active
-
2017
- 2017-11-30 ZA ZA2017/08145A patent/ZA201708145B/en unknown
- 2017-12-13 IL IL256297A patent/IL256297B/en active IP Right Grant
- 2017-12-15 CL CL2017003226A patent/CL2017003226A1/es unknown
- 2017-12-15 DO DO2017000298A patent/DOP2017000298A/es unknown
- 2017-12-19 CO CONC2017/0012995A patent/CO2017012995A2/es unknown
-
2019
- 2019-11-06 US US16/675,634 patent/US20200079759A1/en not_active Abandoned
-
2020
- 2020-12-29 CY CY20201101223T patent/CY1123853T1/el unknown
-
2021
- 2021-10-06 US US17/495,115 patent/US20230047296A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517731A5 (enExample) | ||
| US11912686B2 (en) | LPA receptor antagonists and uses thereof | |
| TWI541241B (zh) | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 | |
| US11713298B2 (en) | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | |
| AU2014346919A1 (en) | Compositions and methods for modulating Farnesoid X receptors | |
| CN107849043B (zh) | 用于制备(4s)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氢-1,6-萘啶-3-甲酰胺的方法 | |
| WO2018049068A1 (en) | N-acyl amino acid compounds and methods of use | |
| US10059677B2 (en) | Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof | |
| JP2019532033A (ja) | オルトミクソウイルス感染症を治療するのに有用な縮合三環式ピリダジノン化合物 | |
| JP2022520442A (ja) | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン | |
| WO2021247215A1 (en) | Lpa receptor antagonists and uses thereof | |
| KR102493943B1 (ko) | 포유류 티로신 키나제 ROR1 활성의 저해제로서 유용한 2-페닐-3H-이미다조[4,5-b]피리딘 유도체 | |
| JP2024525900A (ja) | グルカゴン様ペプチド－１受容体モジュレーター及びその使用 | |
| JP6275881B2 (ja) | デュオカルマイシンのプロドラッグを製造するための改良された方法 | |
| JP2015524481A (ja) | （ｓ）−３−（４−（（４−（モルホリノメチル）ベンジル）オキシ）−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオン及びその医薬として許容し得る形態の製造プロセス | |
| JP2013521301A5 (enExample) | ||
| US11932631B2 (en) | Process for preparing aficamten | |
| KR20180006450A (ko) | 우레아 유도체 또는 그의 약리학상 허용되는 염 | |
| JP2008516935A (ja) | フェノキシベンズアミド化合物の製造方法 | |
| KR20160118359A (ko) | 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조 | |
| JP7406692B2 (ja) | 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法 | |
| US20120245152A1 (en) | 3-(biaryoxy)propionic acid derivative | |
| JP2001526257A (ja) | ナフタレン誘導体 | |
| US11104650B2 (en) | Process for production of 2-chloro-4-nitroimidazole derivatives | |
| US20150225376A1 (en) | Efficient Process for the Preparation of Lapatinib and Salts thereof by Means of New Intermediates |